Long-term lymphoma risk in thiopurine-treated inflammatory bowel disease: A 15-year propensity-matched cohort study

Table 4 Odds ratio for lymphoma outcomes for patients with Crohn’s disease taking thiopurines vs Crohn’s disease taking 5-aminosalicylic acid and not taking thiopurines or biologics

Outcomes	Events in CD with thiopurines	Events in CD with 5-ASA	OR (95%CI)	P value
Overall lymphoma
1 year	11	11	1.00 (0.43-2.30)	09985
3 years	21	17	1.24 (0.65-2.34)	0.5168
5 years	29	21	1.36 (0.77-2.41)	0.253
10 years	45	25	1.80 (1.10-2.94)	0.0169
15 years	45	31	1.39 (0.87-2.10)	0.1626
Hodgkin lymphoma
1 year
3 years
5 years
10 years
15 years
Non-Hodgkin lymphoma
1 year	≤ 10	11	0.91 (0.39-2.14)	0.8359
3 years	19	17	1.12 (0.58-2.15)	0.739
5 years	27	21	1.29 (0.73-2.28)	0.386
10 years	40	25	1.60 (0.97-2.64)	0.063
15 years	37	27	1.37 (0.83-2.25)	0.211
B-cell lymphoma
1 year	≤ 10	≤ 10
3 years	15	18	0.83 (0.42-1.65)	0.406
5 years	24	22	1.09 (0.61-1.95)	0.769
10 years	36	27	1.33 (0.81-2.20)	0.257
15 years	34	27	1.26 (0.76-2.08)	0.370
T-cell/natural killer cell lymphoma
1 year	≤ 10	≤ 10
3 years	≤ 10	≤ 10
5 years	≤ 10	≤ 10
10 years	≤ 10	≤ 10
15 years	≤ 10	≤ 10

Odds ratios of lymphoma outcomes at the 1-year, 3-year, 5-year, 10-year, and 15-year follow-up among propensity score-matched cohorts of patients with Crohn’s disease taking thiopurines vs patients with Crohn’s disease taking 5-aminosalicylic acid and not taking thiopurines or biologics. Outcomes are presented as event counts with percentage and corresponding odds ratios with 95% confidence intervals. All analyses reflect matched sample sizes of 18111 per group. CD: Crohn’s disease; 5-ASA: 5-aminosalicylates; OR: Odds ratio; CI: Confidence interval.